Efficacy of the Mepitel® Film on the Prevention of Radiodermatitis in the Inguinal Fold.
Launched by JULES BORDET INSTITUTE · Nov 2, 2020
Trial Information
Current as of April 30, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with external beam radiotherapy of the bilateral inguinal nodal region, with at least 25 fractions of 1.8-2Gy per fraction.
- Exclusion Criteria:
- • Re-irradiation.
- • Pregnancy.
- • Patients under the age of 18.
- • Patients not willing to participate (no informed consent).
About Jules Bordet Institute
The Jules Bordet Institute is a prestigious cancer research and treatment center located in Brussels, Belgium, dedicated to advancing oncology through innovative clinical trials and multidisciplinary care. As a leading sponsor of clinical research, the institute focuses on developing novel therapeutic approaches and improving patient outcomes in various cancer types. With a commitment to scientific excellence and collaboration, the Jules Bordet Institute leverages cutting-edge technologies and a robust network of healthcare professionals to foster breakthroughs in cancer treatment and enhance the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials